GMT Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

GMT Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$110M	Sell	581,000 -57,500	-9%	-$10M	5.01%	3
2025 Q4	$109M	Sell	638,500 -154,300	-19%	-$23.7M	5.66%	4
2025 Q3	$104M	Buy	792,800 +24,400	+3%	+$2.93M	4.74%	6
2025 Q2	$81.5M	Buy	768,400 +95,500	+14%	+$10.4M	3.41%	12
2025 Q1	$83.5M	Buy	672,900 +164,100	+32%	+$21.4M	4.43%	9
2024 Q4	$62.7M	Buy	508,800 +296,800	+140%	+$35M	3.05%	14
2024 Q3	$23.6M	Buy	+212,000	New	+$23.2M	0.94%	23

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GMT Capital's JAZZ Position: Q1 2026 in Review

GMT Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 9% in Q1 2026, selling an estimated $10M and leaving 581,000 shares worth $110M. The position accounts for 5.01% of the portfolio, ranked #3.

GMT Capital first reported a position in JAZZ in Q3 2024 and has held it in 7 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

GMT Capital held 581,000 shares of Jazz Pharmaceuticals worth $110M as of Q1 2026.
GMT Capital sold 57,500 Jazz Pharmaceuticals shares in Q1 2026, an estimated $10M.
Jazz Pharmaceuticals made up 5.01% of GMT Capital's portfolio in Q1 2026, its #3 holding.
GMT Capital first reported a position in Jazz Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on GMT Capital's 13F filing for Q1 2026, filed 15 May 2026.